Xlear, Inc., U.S. v.

The FTC, acting through DOJ, sued Xlear, Inc. in October 2021 under the COVID-19 Consumer Protection Act, alleging the Utah-based company falsely marketed its saline nasal sprays as effective for preventing and treating COVID-19. The core violation was unsubstantiated efficacy claims tied to a serious infectious disease. In March 2025, DOJ agreed to dismiss the case with prejudice, resulting in no final judgment or penalty against Xlear.